A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Novartis
National Cancer Institute (NCI)
Novartis
OHSU Knight Cancer Institute
Pfizer
Medical College of Wisconsin
M.D. Anderson Cancer Center
Institut Bergonié
Novartis
Novartis
Novartis
Pfizer
Novartis
Fred Hutchinson Cancer Center
Novartis
Pfizer
Emory University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Bristol-Myers Squibb
Novartis
Novartis
OHSU Knight Cancer Institute
Novartis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Teva Branded Pharmaceutical Products R&D, Inc.
Ariad Pharmaceuticals
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
OHSU Knight Cancer Institute
Novartis
Bristol-Myers Squibb